ERNEST HAWK to Precancerous Conditions
This is a "connection" page, showing publications ERNEST HAWK has written about Precancerous Conditions.
Connection Strength
1.614
-
MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila). 2013 Mar; 6(3):196-205.
Score: 0.275
-
From Premalignant Biology to Precision Interception: Connecting the Dots with a Curated Collection of Invited Articles. Cancer Prev Res (Phila). 2023 07 05; 16(7):365-367.
Score: 0.141
-
Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med. 2001 Jan 16; 134(2):158-60.
Score: 0.119
-
Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine. 2019 Apr; 42:296-303.
Score: 0.104
-
Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol. 2018 10 01; 29(10):2061-2067.
Score: 0.101
-
Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol. 2018 08 01; 4(8):1085-1092.
Score: 0.100
-
Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res. 2017 11 15; 77(22):6119-6130.
Score: 0.094
-
The somatic mutation landscape of premalignant colorectal adenoma. Gut. 2018 07; 67(7):1299-1305.
Score: 0.092
-
Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
Score: 0.088
-
Precancerous lesions of the digestive tract. The 18th Annual Symposium of the European Cancer Prevention Organization. Maastricht, The Netherlands. 12-14 October 2000. Abstracts. Eur J Cancer Prev. 2000 Dec; 9(6):443-63.
Score: 0.059
-
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):21-31.
Score: 0.049
-
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007 Apr 04; 99(7):545-57.
Score: 0.046
-
Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.
Score: 0.045
-
Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res. 2006 Jul 01; 66(13):6851-60.
Score: 0.043
-
Colorectal cancer prevention. J Clin Oncol. 2005 Jan 10; 23(2):378-91.
Score: 0.039
-
A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 01; 10(19):6502-11.
Score: 0.038
-
Aspirin: still learning about the wonder drug. Gut. 2003 Nov; 52(11):1535-6.
Score: 0.036
-
Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):593-6.
Score: 0.035
-
A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst. 2002 Jul 03; 94(13):1001-9.
Score: 0.033
-
Primary cancer prevention trials. Hematol Oncol Clin North Am. 2000 Aug; 14(4):809-30.
Score: 0.029
-
Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999 Mar; 20(3):425-30.
Score: 0.026
-
Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev. 1996 Dec; 5 Suppl 2:79-85.
Score: 0.022